Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cognition Therapeutics Inc

NASDAQ: CGTX · Life Sciences · 3 alerts · CIK 1455365

Share price
$0.6388Close, Nov 16
Market cap
$60.8M
Shares outstanding
95.1MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cognition Therapeutics Inc filings on SEC EDGAR ↗

6:06 AM ET 8-K
Business Update

Cognition Therapeutics Business Update

Cognition Therapeutics has reached alignment with the FDA on the design of its planned Phase 3 registrational study for zervimesine (CT1812) in patients with dementia with Lewy bodies (DLB). The study will focus on mild-to-moderate DLB patients using hallucinations (NPI-2) as a primary endpoint and daily function (ADCS-ADL) as a secondary endpoint.

Counterparty
FDA
Term
9 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.